ADDvise Group’s subsidiary MRC Systems has received an order from Rafarm, a leading pharmaceutical company based in Greece. The order is worth approximately EUR 2.6 million. The order involves design, paneling, and installation of a cleanroom and associated accessories. Delivery of the order is scheduled to be completed during Q4 2025. For further information, please…
Read moreADDvise Group’s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm worth approximately SEK 72 million. The allocation decision involves the delivery of blood specimen collection equipment over a four-year period, commencing in May 2025. The allocation decision can be appealed up until December 20, 2024. For further information, please contact: Staffan…
Read moreADDvise is exploring the possibility of divesting its subsidiary AB Germa. Germa has shifted its focus primarily towards defense equipment, which falls outside of ADDvise’s core business within life science. ADDvise is therefore evaluating options to find a new owner who can further develop Germa and maximize its full potential within the defense segment. Since…
Read moreADDvise Group’s subsidiary MRC Systems has received an order from Orbitworks, a company specialized in advanced technology, based in United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves design, paneling, and installation of a cleanroom and associated accessories. Delivery of the order is scheduled to be completed during Q2 2025.…
Read moreTo enhance focus and efficiency, ADDvise is restructuring its two existing business areas, Lab and Healthcare, into separate operational units, each led by a dedicated director. This new structure is designed to optimize the organization, establish a clearer strategic focus, and strengthen the foundation for both organic growth and acquisitions. Additionally, the structure facilitates valuable…
Read moreThe third quarter of 2024 showed strong order intake, +17%, and net revenue growth, +26%. Despite challenging comparative figures from 2023, especially in the pharmaceutical sector and rental of equipment for clinical trials, we showed robust development. Excluding these segments, we saw organic growth of 6% for January−September, reflecting the strength of our business. July–September…
Read moreIn accordance with the resolution at the Annual General Meeting 2022 of ADDvise Group, the nomination committee for the Annual General Meeting 2025 shall comprise of representatives of the three largest shareholders by votes, according to the shareholders’ register as of 30 June 2024 maintained by Euroclear Sweden, and of the chairman of the board…
Read moreMedia, investors and analysts are invited to attend a presentation of the interim report for the period July 1 – September 30, 2024. The presentation will take place on October 24, 2024, at 14:00 (CEST) / 08:00 AM (EST). CEO, Staffan Torstensson, and Interim CFO, Johan Irwe, will present the report in a webcast and…
Read moreADDvise Group’s subsidiary MRC Systems has received an order from Medisept. The company is a medical device manufacturer for the healthcare industry based in Oran, Algeria. The order is worth approximately USD 1.3 million. The order involves design, paneling, and installation of a cleanroom and associated accessories for a new medical device manufacturing facility with…
Read moreADDvise Group’s subsidiary Germa has received an order from Saab AB (publ). The order has a total value of approximately SEK 32.5 million. The order relates to the delivery of equipment and related components. The deliveries will be separated and are expected to be made during 2025 as agreed between Germa and Saab. Payment will…
Read moreADDvise Group AB has previously convened an extraordinary general meeting on 29 August 2024 to elect a new board member. Major shareholders in the company, who together represent approximately 30 percent of the shares in the company, have proposed that a new board member shall be elected to the board of directors to replace Staffan…
Read moreThe chairman of the board and incoming CEO Staffan Torstensson has today, privately and through companies, divested 610,000 shares of series A to Kenneth Lindqvist, one of the major shareholders of ADDvise, privately and through companies. The total purchase price for the shares amounted to SEK 9,150,000. In conjunction with the divestment of the shares…
Read moreThe departing CEO Rikard Akhtarzand has agreed with Kenneth Lindqvist, one of the major shareholders of ADDvise, to divest 2,500,000 shares of series A to Kenneth Lindqvist, privately and through companies. The total purchase price for the shares amounts to SEK 37,500,000. The divestment of the shares is subject to approval by the Swedish Inspectorate…
Read moreThe second quarter saw continued robust revenue growth and improved profit. Organic growth remains burdened by challenging comparables from 2023 driven by very strong sales in pharmaceuticals and rental of equipment for clinical trials, but with organic order intake well back in positive territory with several large new orders, we are optimistic about the second…
Read moreADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the extraordinary general meeting on 29 August 2024 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST. NOTIFICATION Shareholders wishing to attend the general meeting must: i) be registered in the share register kept by Euroclear Sweden AB on…
Read moreThe board of directors of ADDvise Group announces today that the chairman of the board, Staffan Torstensson, is appointed CEO of the company, effective September 1, 2024. In light of this transition, the board will convene an extraordinary general meeting in the near future to elect Per Åhlgren as board member and new chairman of…
Read moreADDvise Group’s interim report for the period January 1 – June 30, 2024 will be published on July 18, 2024 at 07:45 (CEST). Investors, analysts, and other stakeholders are invited to a webcast and conference call at 14:00 (CEST) / 08:00 AM (EST) the same day where CEO Rikard Akhtarzand and CFO Oliver Humlen will…
Read moreAxelerist, an ADDvise Group company, has received an order from Vertex Pharmaceuticals, a global biotechnology company, for the sale and rental of medical and laboratory equipment. The order value amounts to USD 1.4 million. Delivery will take place over a four-year period starting in Q3 2024. For further information, please contact: Rikard Akhtarzand, CEO +46…
Read moreADDvise Group AB (publ) ("ADDvise Group") has initiated the process of listing the company's A and B shares on Nasdaq Stockholm. The change of listing venue is expected to be completed in the first quarter of 2025. As part of the continued development of ADDvise Group, the company has for some time reviewed the possibility…
Read moreADDvise Group AB (publ), reg. no. 556363-2115, has held its annual general meeting on 3 May 2024 at 10 a.m. CEST at the company’s premises at Grev Turegatan 30 in Stockholm. At the meeting it was resolved on, among other things, re-election of Staffan Torstensson, Fredrik Celsing, Johanne Brændgaard and Anna Ljung as board members,…
Read moreADDvise Group has appointed Oliver Humlen as new CEO, effective September 1, 2024. He will succeed Rikard Akhtarzand who will take up the position as CEO of Your.Online, a European serial acquirer platform backed by Strikwerda Investments. Rikard will remain a significant and long-term shareholder in ADDvise Group and is nominated to the Board of…
Read moreMRC Systems, an ADDvise Group company, has received an order from leading Omani biopharmaceutical company Opal Bio Pharma. The initial order value amounts to USD 11.3 million with an extension option amounting to an additional USD 6.8 million. The order involves the design, supply, installation and validation of cleanroom panelling, HVAC and accessories for a…
Read moreOn 4 April 2024, ADDvise Group AB (publ) (“ADDvise”) issued senior secured bonds in an amount of USD 60 million, under a total framework of USD 200 million (the “Bonds”). Pursuant to the terms and conditions for the Bonds, ADDvise has undertaken to apply for admission to trading of the Bonds on the corporate bond…
Read moreThe first quarter saw a continued favourable revenue development. The Lab segment delivered strong organic growth whereas our pharmaceuticals business affected the Group negatively. The changing product mix resulted in lower margins. Work continued to optimise the capital structure and profit for the period improved.
Read moreADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from the Kanta-Häme region worth EUR 1.25 million. The allocation decision pertains to the delivery of x-ray equipment to three hospitals in the region during 2024 and early 2025. The allocation decision is subject to a customary appeals period. For further information, please…
Read moreADDvise Group’s interim report for the period January 1 – March 31, 2024 will be published on April 18, 2024 at 07:45 (CEST). Investors, analysts, and other stakeholders are invited to a webcast and conference call at 14:00 (CEST) / 08:00 AM (EST) the same day where CEO Rikard Akhtarzand and CFO Oliver Humlen will…
Read moreToday, ADDvise Group AB (publ) is publishing the annual report and the sustainability report for 2023. Both reports are available on ADDvise’s website: www.addvisegroup.com. The annual report and the sustainability report are published in Swedish and English. The Swedish versions represent the originals. For further information, please contact: Rikard Akhtarzand, CEO +46 (0)76-525 90 71…
Read moreADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the annual general meeting on 3 May 2024 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST. NOTIFICATION Shareholders wishing to attend the annual general meeting must: i) be registered in the share register kept by Euroclear Sweden AB on the…
Read moreADDvise Group AB (publ) (the “Company”) announces today that it has successfully placed senior secured bonds in an amount of USD 60 million under a framework of USD 200 million with a tenor of 3 years (the “New Bonds” or the “Bond Issue”). The New Bonds will carry floating rate interest of SOFR plus 4.25…
Read moreADDvise Group AB (publ) (“ADDvise” or the “Company”) has mandated Pareto Securities AB and Skandinaviska Enskilda Banken AB (publ) to arrange a series of credit investor meetings commencing on 18 March 2024. To better align the Company’s long-term funding with its operational currency exposure, the Company considers, subject to inter alia market conditions, the issuance…
Read moreNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.…
Read moreNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.…
Read moreTo the annual general meeting (AGM) of ADDvise Group AB (publ) on 3 May 2024, the nomination committee has decided to propose re-election of Fredrik Celsing, Staffan Torstensson, Johanne Brændgaard and Anna Ljung as members of the board of directors. In addition, the nomination committee proposes election of Thomas Eklund. Erland Pontusson has declined re-election.…
Read moreADDvise delivers its strongest quarter to date and surpasses financial targets for 2023. Net sales increased by 24% and EBITDA amounted to a record SEK 126 million, corresponding to an EBITDA margin of 32%.
Read moreADDvise Group’s year-end report for the period January 1 – December 31, 2023 will be published on February 22, 2024 at 07:45 (CET). Investors, analysts and other stakeholders are invited to a webcast and conference call at 14:00 (CET) / 08:00 AM (ET) the same day where CEO Rikard Akhtarzand and CFO Oliver Humlen will…
Read moreADDvise Group’s subsidiary Labplan has received an order from the pharmaceutical company Eli Lilly. The order is worth approximately EUR 2.1 million and involves advanced laboratory instruments for quality control purposes. The instruments will be used in a new manufacturing facility for biologic pharmaceuticals in Limerick, Ireland. Delivery of the order is scheduled to the…
Read moreOn 20 November 2023, ADDvise Group successfully issued senior secured bonds in an amount of SEK 450 million, under a total framework of SEK 2,000 million. Following the bond issue, in total SEK 1,450 million is outstanding under the framework. Pursuant to the terms and conditions for the bonds, ADDvise has undertaken to apply for…
Read moreADDvise Group’s subsidiary MRC Systems has received an order from SaudiVax. The company is a biotechnology company specialized in the development and production of vaccines and biopharmaceuticals. The order is worth approximately USD 2.5 million and involves design, installation, and commissioning of a cleanroom and associated accessories. The facility is located in the Kingdom of…
Read more